Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1919-1929

  Rubin, Richard R ^a,c   Peyrot, Mark ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MARYLAND   (United States)

^c NONE   (United States)

Author keywords

Diabetes mellitus type 1; Diabetes mellitus type 2; Patient satisfaction; Pramlintide

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PRAMLINTIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTPRANDIAL STATE; QUESTIONNAIRE; REGRESSION ANALYSIS; WEIGHT CONTROL;

ADULT; AMYLOID; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34548118251     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210804     Document Type: Article

References (31)

1. National Institute of Diabetes, Digestive and Kidney Disorders. Available from http://diabetes.niddk.nih.gov/dm/pubs/statistics#7 [Last accessed 5 June 2007]
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-32
3. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
5. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(Suppl 1):S4-41
6. AACE Diabetes Medical Guidelines Task Force. AACE diabetes guidelines. Endocr Pract 2002;8(Suppl 1):41-65
7. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
8. The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 1993;329:977-86
9. The Diabetes Control and Complications Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711-21
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
11. Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994;17:267-74
12. Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997;20:562-7
13. Van der Does FE, De Neeling JN, Snoek FJ, et al. Randomized study of two different levels of glycemic control within the acceptable range in type 2 diabetes. Diabetes Care 1998;21:2085-93
14. 1c. Diabetes Care 2003;26:881-5
15. Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005;54:1-7
16. Unger RH. Glucagon physiology and pathophysiology. NEJM 1971;285:443-9
17. Young AA. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diab 1997;4:282-90
18. Young AA, Gedulin BR, Vine W, et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995;38:642-8
19. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997;46:67-70
20. Rushing PA, Lutz TA, Seeley RJ, et al. Amylin and insulin interact to reduce food intake in rats. Horm Metab Res 2000;32:62-6
21. Kruger DF, Aronoff SL, Edelman SV. Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostatis. Diabetes Educ 2007;33(Suppl 2):32S-48
22. Kong MF, Stubbs TA, King P, et al. The effect of a single dose of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998:41:577-83
23. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-48
24. Hollander PA, Levy P, Fineman MS, et al. Pramlintide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003;26:784-90
25. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-95
26. Symlin [package insert]. San Diego, CA, USA. Amylin Pharmaceuticals, 2005
27. Whitehouse F, Kruger DF, Fineman MS, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724-30
28. Ratner RE, Dickey R, Fineman MS, et al. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial. Diabet Med 2004;21:1204-12
29. Peyrot M, Rubin RR. Assessing health-related quality of life (HRQOL): the Insulin Delivery System Questionnaire (IDSRQ). Diabetes Care 2005;28:53-8
30. Cohen J. Statistical power analysis for the behavioral sciences. London: Academic Press, 1969
31. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92